Morgan Stanley Maintains Equal-Weight on BioNTech, Lowers Price Target to $119
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) but lowered the price target from $124 to $119.
July 11, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Equal-Weight rating on BioNTech but lowered the price target from $124 to $119.
The news is directly related to BioNTech and is likely to influence investor sentiment. The lowering of the price target may suggest a slightly less optimistic outlook for the company, but the maintenance of the Equal-Weight rating indicates that the analyst still sees the stock as fairly valued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100